MDGL

Madrigal Pharmaceuticals
D

MDGL

547.04
USD
17.55
(3.31%)
مغلق
حجم التداول
0
الربح لكل سهم
-7
العائد الربحي
-
P/E
-43
حجم السوق
12,424,055,197
أصول ذات صلة المقالات
المزيد

العنوان: Madrigal Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.